Precigen (PGEN) Long-Term Debt Repayments (2013 - 2023)
Precigen (PGEN) posted quarterly Long-Term Debt Repayments of $13.9 million for Q2 2023, up 12193.81% year-over-year from N/an in Q2 2022, and down 52.63% quarter-over-quarter from $29.3 million in Q1 2023.
Analysis
Precigen (PGEN) Long-Term Debt Repayments (2013 - 2023) Analysis & Trends
Precigen (PGEN) has reported Long-Term Debt Repayments for 11 consecutive years, with $13.9 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Long-Term Debt Repayments rose 12193.81% year-over-year to $13.9 million; the TTM figure through Mar 2024 stood at $13.9 million (down 92.47% YoY), while the FY2023 annual figure was $43.2 million, down 72.17% from the prior year.
- Long-Term Debt Repayments declined to $13.9 million in Q2 2023 per PGEN's latest filing, from $29.3 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $115.7 million in Q3 2022 and bottomed at $113000.0 in Q2 2022.
- Historically, Long-Term Debt Repayments has averaged $11.1 million across 5 years, with a median of $137500.0 in 2019.
- Annual changes were most pronounced in 2019 — Long-Term Debt Repayments slipped 29.9% — and 2022, when it jumped 98817.95%.
- Precigen's Long-Term Debt Repayments stood at $154000.0 in 2019, then decreased by 22.08% to $120000.0 in 2020, then fell by 4.17% to $115000.0 in 2021, then jumped by 34058.26% to $39.3 million in 2022, then slumped by 64.64% to $13.9 million in 2023.
- Business Quant data shows PGEN's Long-Term Debt Repayments at $13.9 million in Q2 2023, $29.3 million in Q1 2023, and $39.3 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 13.89 Mn |
| Mar 31, 2023 | 29.33 Mn |
| Dec 31, 2022 | 39.28 Mn |
| Sep 30, 2022 | 115.73 Mn |
| Jun 30, 2022 | 113,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 117,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Mar 31, 2021 | 116,000.00 |
| Dec 31, 2020 | 120,000.00 |
| Sep 30, 2020 | 117,000.00 |
| Jun 30, 2020 | 121,000.00 |
| Mar 31, 2020 | 132,000.00 |
| Dec 31, 2019 | 154,000.00 |
| Sep 30, 2019 | 143,000.00 |
| Jun 30, 2019 | 143,000.00 |
| Mar 31, 2019 | 178,000.00 |
| Dec 31, 2018 | 138,000.00 |
| Sep 30, 2018 | 204,000.00 |